← All Kezar Life Sciences, INC filings

Kezar Life Sciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KZR
Kezar Life Sciences, INC
10-K: Kezar Life Sciences Reports 2024 Results, Focuses on Autoimmune Hepatitis Program
Kezar Life Sciences details its 2024 financial performance and strategic shift towards developing zetomipzomib for autoimmune hepatitis.
NASDAQ
KZR
Kezar Life Sciences, INC
10-K: Kezar Life Sciences Details Capital Structure and Anti-Takeover Provisions in 10-K Filing
Kezar Life Sciences' 10-K filing outlines the company's capital structure, including authorized shares of common and preferred stock, and details anti-takeover provisions.